MyFinsight
Home
Blog
About
Contact
Download
Download image
Net income (loss)
$4,623,049
In-process research and
development accrued...
-$3,000,000
Other current assets
-$506,960
Accounts payable,
accrued expenses and...
$63,326
Operating lease
right-of-use assets and...
-$4,405
Net cash provided by
(used in) operating...
$5,357,313
Canceled cashflow
$2,840,427
Net increase
(decrease) in cash and cash...
-$91,150,360
Canceled cashflow
$5,357,313
Taxes paid related to
net share...
-$634,044
Maturities of short-term
investments
$27,654,000
Stock-based compensation
expense
-$2,040,793
Net amortization of
investment discounts and...
$799,634
Net cash provided by
(used in) financing...
-$92,159,285
Canceled cashflow
$634,044
Net cash provided by
(used in) investing...
-$4,318,991
Effect of exchange rate
and valuation...
-$29,399
Canceled cashflow
$27,654,000
something is missing
-$92,772,958
Cash proceeds from
the issuance of...
-$20,371
Purchase of short-term
investments
$31,972,991
Back
Back
Cash Flow
Monopar Therapeutics (MNPR)
Monopar Therapeutics (MNPR)
source: myfinsight.com